Target intelligence / Profile preview

Advanced glycation end-product formation intermediate

Molecular classification
Other
01

Overview

The term **advanced glycation end-product formation intermediates / reactive carbonyl species** refers primarily to highly reactive dicarbonyl compounds such as methylglyoxal, glyoxal, and 3-deoxyglucosone, which are generated during the Maillard reaction as intermediates in the non-enzymatic glycation of proteins, nucleic acids, or lipids[2][3]. These intermediates are not proteins, enzymes, or receptors, but short-lived chemical species whose accumulation leads to the eventual formation of advanced glycation end-products (AGEs)[2][3][5]. Reactive carbonyl species originate from sugar autoxidation, lipid peroxidation, or metabolic pathways (such as glycolysis or the polyol pathway), and are key mediators of "carbonyl stress."[2][3] They covalently modify biological macromolecules, contributing to protein dysfunction, oxidative stress, and inflammation[4]. They are strongly implicated in the pathogenesis of chronic diseases like diabetes, cardiovascular disease, and neurodegeneration due to their damaging effects and their role in AGE formation[1][4]. Pharmacological intervention often focuses on scavenging these intermediates to reduce downstream AGE formation, but targeting them directly is chemically challenging and not equivalent to traditional receptor or enzyme drug targeting[2][3].

Other names
Reactive carbonyl speciesAGE intermediatesMaillard reaction intermediates
02

Mechanism of action

Carbonyl scavenging; Prevention of advanced glycation end-product formation

03

Biological functions

Protein modificationOxidative stress mediationPromotion of carbonyl stress
04

Disease associations

Diabetes and diabetic complicationsCardiovascular diseaseNeurodegenerative diseaseChronic inflammation
05

Safety considerations

Off-target reactivityPotential toxicity of carbonyl scavengers
06

Interacting drugs

Aminoguanidine

2 more in the full profile.

07

Biomarkers

Methylglyoxal (MGO)Glyoxal (GO)3-deoxyglucosone (3-DG)HbA1c

Beyond the preview

Go deeper on Advanced glycation end-product formation intermediate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced glycation end-product formation intermediate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call